On this page
OpenAI partners with Sachin Tendulkar in multi-year India deal
OpenAI partnered with Sachin Tendulkar in India, joining an estimated 23-plus brands he endorses, up from 15 in 2022. His fee remains Rs 8 to 10 crore, while experts question sales impact and warn of overexposure.
One email each morning: the day’s top moves in Indian retail, why each matters and what to watch. Free. Stop any time.
The numbers
Figures from Financial Express,
| Tendulkar brand value in 2025: | $125.9 |
|---|
Why it matters for the brand
Use this deal as a prompt to scrutinize category exclusivity, activation rights and attention dilution before pursuing similarly crowded celebrity partnerships.
What to track next
- Launch of Tendulkar-led ChatGPT campaigns in India
- OpenAI disclosure of India usage or paid-adoption trends
- Campaign research showing ChatGPT recall and brand attribution
- New additions to or departures from Tendulkar's endorsement roster
Likely next moves
Our read of what comes next — analysis, not reported by the source.
- OpenAI is likely to feature Tendulkar in India-focused awareness campaigns, with practical ChatGPT demonstrations helping connect celebrity attention to product use.
- Tendulkar is likely to promote OpenAI alongside his existing endorsements, increasing competition for attention within his commercial roster.
- Indian customers may try ChatGPT following the campaign without immediately becoming paying users, making sustained usage a more demanding test than initial interest.
- Other Tendulkar-endorsed brands may seek more distinctive campaign positioning as his expanding roster raises the risk of overlapping brand associations.
The counter-case
The case against this reading — not reported by the source.
A celebrity partnership is not evidence of sales growth or durable AI adoption. Tendulkar’s expanding endorsement roster could dilute attention and credibility, while the reported deal offers no demonstrated retail impact. The increase from 15 to an estimated 23-plus brands measures endorsement volume, not commercial effectiveness.
The source
Published
First seen